Full coverage

News about Semaglutide • T2D • PAD

Top news

Semaglutide Shows Benefits for PAD Across T2D Subgroups

17 hours ago

By Alicia Ault

EU drugs regulator to allow Novo Nordisk to include heart condition in Ozempic label

2 days ago

Ozempic outperforms another diabetes drug for reducing stroke risk

8 days ago

Novo Nordisk: CHMP gives positive opinion for PAD

Yesterday

All coverage

Semaglutide may improve stroke risk vs. empagliflozin for diabetes

2 days ago

By Scott Buzby

CHMP Backs NVO's Ozempic EU Label Update for Cardiovascular Indication

21 hours ago

ADA 2025: Oral Semaglutide Demonstrates Cardiovascular Benefits in SOUL Trial

2 days ago

By Kennedy Ferruggia

Pill form of popular weight-loss drug lowers heart risks

7 days ago

By Julie Corliss

Novo Nordisk (NVO) Receives EU Panel's Nod for Ozempic Label Update

23 hours ago

breakingthenews.net

EU recommends Ozempic for treating arterial issue

2 days ago

Semaglutide Offers Functional and Vascular Gains in PAD and T2D, with Subodh Verma, MD, PhD

18 hours ago

By Subodh Verma

Longview News-Journal

Oral Semaglutide Significantly Improves Cardiovascular Outcomes in Individuals with Type 2 Diabetes

3 days ago

Zacks Investment Research

CHMP Backs NVO's Ozempic EU Label Update for Cardiovascular Indication

21 hours ago

ADA 2025: Semaglutide Shows Promise in Improving Mobility for Patients With Diabetes and Peripheral Arterial Disease

3 days ago

By Kennedy Ferruggia

STRIDE: Semaglutide Reduces Progression of PAD by 54% in Type 2 Diabetes

4 days ago

By Patrick Campbell

Novo Nordisk A/S: Ozempic® receives EU recommendation in peripheral arterial disease, cementing the broad benefits of semaglutide for people with type 2 diabetes and comorbidities

2 days ago

Semaglutide Increases Walking Capacity in Patients with Peripheral Artery Disease and Type 2 Diabetes

4 days ago

Search

Clear search

Close search

Google apps

Main menu